Chicago Partners Investment Group LLC Grows Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Chicago Partners Investment Group LLC raised its holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 15.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 20,559 shares of the biotechnology company’s stock after acquiring an additional 2,688 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Iovance Biotherapeutics were worth $157,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of IOVA. Annandale Capital LLC purchased a new stake in shares of Iovance Biotherapeutics in the 3rd quarter valued at about $32,000. Clear Street Markets LLC purchased a new position in shares of Iovance Biotherapeutics during the 3rd quarter valued at about $35,000. Quadrant Capital Group LLC raised its holdings in shares of Iovance Biotherapeutics by 1,227.8% during the 4th quarter. Quadrant Capital Group LLC now owns 5,059 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 4,678 shares in the last quarter. Pathstone Family Office LLC purchased a new position in shares of Iovance Biotherapeutics during the 3rd quarter valued at about $48,000. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Iovance Biotherapeutics by 284.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 7,541 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 5,577 shares in the last quarter. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on IOVA shares. Piper Sandler raised their price objective on Iovance Biotherapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Thursday, March 14th. JMP Securities raised their price objective on Iovance Biotherapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a report on Tuesday, February 20th. HC Wainwright reaffirmed a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Friday, May 31st. Barclays lifted their price target on Iovance Biotherapeutics from $18.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, February 29th. Finally, Chardan Capital lifted their price target on Iovance Biotherapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Tuesday, February 20th. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Iovance Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $24.64.

Iovance Biotherapeutics Stock Performance

Shares of IOVA stock opened at $8.00 on Wednesday. The firm has a market cap of $2.24 billion, a P/E ratio of -4.44 and a beta of 0.81. Iovance Biotherapeutics, Inc. has a fifty-two week low of $3.21 and a fifty-two week high of $18.33. The business’s 50 day moving average price is $10.66 and its 200-day moving average price is $10.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.03. The firm had revenue of $0.72 million for the quarter, compared to analyst estimates of $1.99 million. Iovance Biotherapeutics had a negative return on equity of 71.45% and a negative net margin of 23,615.70%. The business’s quarterly revenue was up 71400.0% compared to the same quarter last year. During the same period last year, the company earned ($0.50) EPS. As a group, equities analysts predict that Iovance Biotherapeutics, Inc. will post -1.35 EPS for the current year.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.